Share
Equitable Access to High-Cost Pharmaceuticals
£ 107.10
£ 119.00
You save: £ 11.90
Choose the list to add your product or create one New List
✓ Product added successfully to the Wishlist.
Go to My WishlistsIt will be shipped from our warehouse between
Wednesday, June 19 and
Monday, June 24.
You will receive it anywhere in United Kingdom between 1 and 3 business days after shipment.
Synopsis "Equitable Access to High-Cost Pharmaceuticals"
Equitable Access to High-Cost Pharmaceuticals seeks to aid the development and implementation of equitable public health policies by pharmaco-economics professionals, health economists, and policymakers. With detailed country-by country analysis of policy and regulation, the Work compares and contrasts national healthcare systems to support researchers and practitioners identify optimal healthcare policy solutions. The Work incorporates chapters on global regulatory changes, health technology assessment guidelines, and competitive effectiveness research recommendations from international bodies such as the OECD or the EU. Novel policies such as horizon scanning, managed-entry agreement and post-launch monitoring are considered in detail. The Work also thoroughly reviews novel pharmaceuticals with particular research interest, including cancer drugs, orphan medicines, Hep C, and personalized medicines.Evaluates impact and efficacy of current access policies and pricing regulation of high-cost drugsIncorporates existing guidelines and recommendations by international organizationsCompares and contrasts how different countries fund and police high-cost drug accessExplores novel and emergent policies, including managed entry agreement, analysis of real world data and differential pricingReviews novel pharmaceuticals of current research interest
- 0% (0)
- 0% (0)
- 0% (0)
- 0% (0)
- 0% (0)
All books in our catalog are Original.
The book is written in English.
The binding of this edition is Paperback.
✓ Producto agregado correctamente al carro, Ir a Pagar.
